GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal
This article was originally published in The Pink Sheet Daily
Acquisition more than doubles GSK’s dermatology sales to $1.5 billion, creating a global specialist business across prescription and OTC drugs.
You may also be interested in...
Denmark’s dermatology-focused Leo Pharma sets up the first of a series of long-term collaborations with clinical researchers to boost its R&D pipeline.
Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe
Danish dermatology specialist Leo Pharma is hunting for new pipeline assets after its next major product – Picato gel – got the green light from Europe’s top regulator.
For about $34 million, Stiefel gets development and commercialization rights in most of the world to a novel, non-steroidal, topical anti-inflammatory compound in Phase II.